Squarepoint Ops LLC Buys New Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Squarepoint Ops LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 196,208 shares of the company's stock, valued at approximately $626,000. Squarepoint Ops LLC owned about 0.29% of Perspective Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of CATX. Millennium Management LLC purchased a new position in shares of Perspective Therapeutics during the fourth quarter worth approximately $4,132,000. Octagon Capital Advisors LP grew its position in Perspective Therapeutics by 62.1% in the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock valued at $7,352,000 after buying an additional 882,528 shares during the last quarter. Affinity Asset Advisors LLC grew its position in Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock valued at $4,147,000 after buying an additional 800,000 shares during the last quarter. Two Sigma Investments LP purchased a new position in Perspective Therapeutics in the 4th quarter valued at $2,075,000. Finally, Walleye Capital LLC grew its position in Perspective Therapeutics by 2,526.2% in the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock valued at $1,518,000 after buying an additional 457,675 shares during the last quarter. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on CATX. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Scotiabank began coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Truist Financial lowered their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 13th. One research analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $12.63.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock traded down $0.01 during midday trading on Thursday, reaching $3.12. The company's stock had a trading volume of 1,233,182 shares, compared to its average volume of 1,070,935. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $16.55. The stock's 50 day simple moving average is $2.29 and its 200 day simple moving average is $2.95.

Insider Buying and Selling at Perspective Therapeutics

In other news, CFO Juan Graham purchased 33,333 shares of the business's stock in a transaction dated Friday, March 28th. The stock was acquired at an average price of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. This represents a 1,649.33% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert F. Williamson III purchased 22,192 shares of the business's stock in a transaction dated Friday, March 28th. The shares were purchased at an average cost of $2.27 per share, with a total value of $50,375.84. Following the purchase, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. The trade was a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 115,696 shares of company stock valued at $256,344. 3.72% of the stock is owned by company insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.